Printer Friendly

FDA ADVISORY PANEL MEETING SCHEDULED FOR ALBUNEX

 FDA ADVISORY PANEL MEETING SCHEDULED FOR ALBUNEX
 SAN DIEGO, June 16 /PRNewswire/ -- Molecular Biosystems Inc.


(NYSE: MB) (MBI) today announced that its cardiac ultrasound contrast imaging agent, Albunex(R), will be reviewed by the Food and Drug Administration's Radiology Device Advisory Panel on July 14, 1992.
 The advisory panel will review the use of Albunex for use with 2-D echocardiography (ultrasound of the heart). Albunex for this application is the first in a product line of planned ultrasound contrast imaging agents. Subsequent applications may include additional cardiovascular indications, including myocardial perfusion, as well as the enhancement of liver and kidney ultrasound imaging.
 Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging, and computed tomography. Its flagship product, Albunex, is currently in the final stages of the FDA's pre-market approval process. MBI's marketing and distribution partners for Albunex include Mallinckrodt Medical Inc., IMCERA Group (NYSE: IMA), Shionogi & Co. Ltd. and Hafslund Nycomed AS.
 -0- 6/16/92
 /CONTACT: Beth Field Wallace of Molecular Biosystems, 619-452-0681/
 (MB IMA) CO: Molecular Biosystems Inc. ST: California IN: MTC SU: EH-KJ -- SD001 -- 0507 06/16/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1992
Words:201
Previous Article:INDE TO ACQUIRE KEAP COMMUNICATIONS
Next Article:CIMCO REPORTS RESULTS FOR FOURTH QUARTER AND FISCAL YEAR
Topics:


Related Articles
EPITOPE'S ORASURE PREMARKET APPROVAL APPLICATION SCHEDULED FOR REVIEW BY FDA ADVISORY PANEL
MOLECULAR BIOSYSTEMS, DIRECTORS AND OFFICERS NAMED IN CLASS ACTION SUIT
MOLECULAR BIOSYSTEMS INC. SUBMITS PMA AMENDMENT TO FDA
MBI ANNOUNCES ALBUNEX(R) APPROVAL IN JAPAN
MBI ANNOUNCES LAUNCH OF ALBUNEX(R) IN JAPAN
ATL'S BREAST ULTRASOUND PMA APPLICATION SCHEDULED FOR FDA PANEL HEARING
GENZYME'S SEPRAFILM TENTATIVELY SCHEDULED FOR FDA ADVISORY PANEL REVIEW
Neurocontrol Corporation Receives Filing Letter
FDA Advisory Panel Recommends Clearance of ALBUNEX(R) Ultrasound Imaging Agent for Use in Diagnosing Fallopian Tube Patency
FDA panel says no to FzioMed's Oxiplex gel.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters